DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20163334

C-reactive protein and Apo B as better predictor of STEMI than lipid profile

Preshant Shrivastava, Anshul Agrawal

Abstract


Background: Total cholesterol, triglycerides, high density lipoprotein and low density lipoproteins are the recommended lipid variables for diagnosis and treatment of coronary artery disease. However, recent information shows the importance of apolipoprotein B and CRP as risk predictors of suspected CAD. Inflammation plays a major role in atherothrombosis and measurement of inflammatory markers such as CRP may provide a promising novel biochemical indicator for detecting individuals at high risk of plaque rupture.

Methods: A total number of 43 cases of acute myocardial infarction with ST elevation myocardial infarction were included in this study. In this study CRP was elevated in more patients than LDL/HDL ratio (60.5% vs 20.9% respectively). Similarly, Apo B was elevated in more number of patients than LDL (72.1% vs 39.5% respectively). Also, Apo B/Apo A1 ratio was elevated in more number of patients than LDL/HDL ratio (51.2% vs 20.9% respectively).

Results: In our study maximum incidence of ST elevation MI was present in age group 56-65 years with youngest of age 28 years and oldest of age 75 years. Out of 43 patients who suffered from STEMI 72.1% were males and only 27.9% were females. Out of 43 cases, 46.5% of cases had anterior wall MI, and 46.3% of the cases had inferior wall MI and only 9.3% of the cases developed anteroseptal wall MI. In our study death was encountered in only 9.3% (N – 4) of the cases.

Conclusions: The results of the current study support the concept that the levels of apolipoprotein B, Apo B/Apo A1 ratio and CRP are strongly related to Coronary artery disease in addition to the conventional lipid profile.


Keywords


CRP, Apo B, STEMI, Lipid profile

Full Text:

PDF

References


Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (The INTERHEART Study). Am Heart J. 1963;65:749-57.

Rifai N, Warnick GR. Lipids, lipoproteins, apolipoproteins and other cardiovascular risk factors. In: Burtis CA, Ashwood ER and Bruns DA, editors. Tietz Text Book Of Clinical Chemistry and Molecular Diagnostics, 4th ed. New Delhi: Elsevier Co. 2006:903-64.

Sharma R, Singh VS. Serum apolipoproteins in the patients of myocardial infarction in different age groups. Ind J Clin Biochem. 2001;16(1):122-6.

Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, et al. Apolipoprotein A1 and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the quebec cardiovascular study. Circulation. 1996;94:273-78.

Gotto AM, Assmann G, Carmena R. The ILIB lipid handbook for clinical practice: Blood lipids and coronary heart disease. 2nd ed. New York: International Lipid Information Bureau; 2000;53:201.

Genest J, Frohlich J, Fodor G, McPherson R. the Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: 2003 update. CMAJ. 2003;169:921-4.

Holme I, Aastveit AH, Junger I, Walldius G. Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein Mortality RISk study (AMORIS). J Intern Med. 2008;264:30-8.

Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51(15):1512-24.

Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB. C-reactive protein and coronary heart disease: a critical review. J Intern Med. 2008;264(4):295-314.

Loidl A, Sevcsik E, Riesenhuber G, Deigner H, Hermetter A. Oxidized Phospholipids in Minimally Modified Low Density Lipoprotein Induce Apoptotic Signaling via Activation of Acid Sphingomyelinase in Arterial Smooth Muscle Cells. J Biol Chem. 2003;278:32921-8.

Kulsoom B, Nazrul SH. Association of serum C-reactive protein and LDL:HDL with myocardial infarction.J Pak Med Assoc. 2006;56(7):318-22.

Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Engl J Med. 2002;347:1557-65.

DeBeer FC, Hind CR, Fox KM.Measurement of serum C-reactive protein in myocardial ischemia and infarction. Br Heart J. 1982;47:239-43.

Sharma R, Singh VS. Serum apolipoproteins in the patients of myocardial infarction in different age groups. Ind J Clin Biochem. 2001;16(1):122-6.

Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with Walldius, Jungner I, Holme I, Aastveit A, Kolar W, Steiner E. High apolipoprotein B, lowapolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026-33.

Sreenivasan RS, Kavitha A, Anush AR, Krishna MP, Renganathan NG Identification and prediction of coronary heart disease in patients with apolipoprotein levels. IJPBS. 2011;1(2):31-42.

Dawar R, Gurtoo A, Singh R. Apo B/ Apo A1 ratio is statistically the best predictor of Myocardial Infarction compared to other lipid ratios. Int J of Pharma and Bio Sciences. 2010;1(2):1.